| Literature DB >> 31620588 |
Abstract
Environmental contaminants are one of the important causal factors for development of various human diseases. In particular, the perinatal period is highly vulnerable to environmental toxicants and resultant dysregulation of fetal development can cause detrimental health outcomes potentially affecting life-long health. Perfluoroalkyl compounds (PFCs), emerging environmental pollutants, are man-made organic molecules, which are widely used in diverse industries and consumer products. PFCs are non-degradable and bioaccumulate in the environment. Importantly, PFCs can be found in cord blood and breast milk as well as in the general population. Due to their physicochemical properties and potential toxicity, many studies have evaluated the health effects of PFCs. This review summarizes the epidemiological and experimental studies addressing the association of PFCs with neurotoxicity and immunotoxicity. While the relationships between PFC levels and changes in neural and immune health are not yet conclusive, accumulative studies provide evidence for positive associations between PFC levels and the incidence of attention deficit hyperactivity disorder and reduced immune response to vaccination both in children and adults. In conclusion, PFCs have the potential to affect human health linked with neurological disorders and immunosuppressive responses. However, our understanding of the molecular mechanism of the effects of PFCs on human health is still in its infancy. Therefore, along with efforts to develop methods to reduce exposure to PFCs, studies on the mode of action of these chemicals are required in the near future.Entities:
Keywords: Environmental pollutants; Health outcomes; Immunotoxicity; Neurotoxicity; Perfluoroalkyl compounds
Year: 2018 PMID: 31620588 PMCID: PMC6784697 DOI: 10.12701/yujm.2018.35.2.156
Source DB: PubMed Journal: Yeungnam Univ J Med ISSN: 2384-0293
Fig. 1.Structures of PFHxS, PFOS, and PFOA. PFHxS, perfluorohexane sulfonic acid; PFOS, perfluorooctane sulfonic acid; PFOA, perfluorooctanoic acid; FOSA, perfluorooctane sulfonamide.
Classification and chemical formula of major PFC congeners
| Classification | CnF2n+1R, where R= | Examples | |
|---|---|---|---|
| Chemical formula | Substances | ||
| Perfluoroalkyl carboxylic acid | -COOH | C7F15COOH | PFOA |
| C8F17COOH | PFNA | ||
| Perfluoroalkane sulfonic acid | -SO3H | C6F13SO3H | PFHxS |
| C8F17SO3H | PFOS | ||
| Perfluoroalkane sulfonamide | -SO2NH2 | C8F17SO2NH2 | FOSA |
PFC, perfluoroalkyl compounds; PFOA, perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; PFOS, perfluorooctane sulfonic acid; FOSA, perfluorooctane sulfonamide.
Summary of PFCs and neurodevelopmental and neurodegenerative impacts
| Study group | Sample | PFCs | Effects | Summary | References |
|---|---|---|---|---|---|
| Danish National Birth Cohort | Maternal serum | PFOS | Start of sit without support at age 18 mon | Negative association between PFOS and start of sit without support | Fei et al. [ |
| A cohort in Cincinnati | Maternal serum | PFOS | Executive function deficits at age 5-8 yr | Positive association between PFOS and executive function deficits | Vuong et al. [ |
| Boston-area birth cohort | Maternal and childhood serum | PFCs | Visual motor abilities | Negative association between serum PFCs and visual motor abilities | Harris et al. [ |
| Taiwan Birth Panel Study and the Taiwan Early-Life Cohort | Cord blood | PFNA | ADHD at age 7 yr | Positive association between cord blood PFNA and ADHD | Lien et al. [ |
| Mid-Ohio Valley C8 cohort | Serum at age 5-18 yr | PFOS, PFHxS | Parental ADHD | Positive association between serum PFCs and parental report of ADHD | Stein and Savitz [ |
| INUENDO cohort | Serum of child | PFOA | Hyperactivity and behavioral problems | Positive association between serum PFOA and hyperactivity and behavioral problems | Hoyer et al. [ |
| Danish National Birth Cohort | Maternal serum | PFOA | ADHD | Positive association between serum PFOA and ADHD | Liew et al. [ |
| A cohort in Italy including Veneto Region | Drinking water | PFCs | Mortality caused by Alzheimer、disease | Positive association between level of PFCs in drinking water and mortality caused by Alzheimer’s disease | Mastrantonio et al. [ |
| Mice | Serum | PFOS, PFOA | Spontaneous behavior and habitation in adult | Positive association between serum PFOS and PFOA and spontaneous behavior and habitation in adult | Johansson et al. [ |
| Mice | Serum | PFOS, PFOA | Neuroprotein expression in developing brain | Positive association between serum PFOS and PFOA and alteration of neuroprotein expression | Johansson et al. [ |
| Mice | Serum | PFHxS | Cognitive disturbance in adult | Positive association between serum PFHxS and cognitive disturbance in adult | Viberg et al. [ |
| Mice | Serum | PFHxS | Neuroprotein expression in developing brain | Positive association between serum PFHxS and alteration of neuroprotein expression | Lee and Viberg [ |
| Cerebellar granule cell | PFOS | Apoptosis | PFOS increases apoptosis via ROS-PKC pathway | Lee et al. [ | |
| Cerebellar granule cell | PFOS | Apoptosis | PFOS increases apoptosis via ERK1/2 pathway | Lee et al. [ | |
| Cerebellar granule cell | PFHxS | Apoptosis | PFHxS increases apoptosis via ERK1/2 pathway | Lee et al. [ | |
| PC12 cells | PFHxS | Apoptosis | PFHxS increases apoptosis via NMDA-ERK1/2 pathway | Lee et al. [ | |
| PC12 cells | PFHxS | Apoptosis | PFHxS increases apoptosis via AMPK pathway | Lee et al. [ |
PFC, perfluoroalkyl compounds; PFOS, perfluorooctane sulfonic acid; PFNA, perfluorononanoic acid; ADHD, attention deficit hyperactivity disorder; PFHxS, perfluorohexane sulfonic acid; PFOA, perfluorooctanoic acid; ROS, reactive oxygen species; PKC, protein kinase C; ERK1/2, extracellular signal-regulated kinase 1/2; NMDA, N-methyl-D-aspartate; AMPK, AMP-activated protein kinase.
Summary of PFCs and immunoregulatory impacts
| Study model | Sample | PFCs | Effects | Summary | References |
|---|---|---|---|---|---|
| Birth cohort of the National Hospital in the Faroe Islands | Serum at age 5 yr | PFOS, PFOA | Diphtheria antibody at age 7 yr | Negative association between PFOS and PFOA and antibody production | Grandjean et al. [ |
| Birth cohort of the National Hospital in the Faroe Islands | Serum at age 5 yr | PFOS, PFOA | Diphtheria antibody at age 13 yr | Negative association between PFOS and PFOA and antibody production | Grandjean et al. [ |
| Norwegian Mother and Child cohort | Maternal serum | PFCs | Rubella antibody at age 3 yr | Negative association between maternal serum PFCs and antibody concentration | Granum et al. [ |
| Hospital-based cohort of Hokkaido | Maternal serum | PFOS, PFHxS | Otitis media, pneumonia, respiratory Syncytial virus infection and varicella | Positive association between maternal serum PFOS and PFHxS infectious diseases | Goudarzi et al. [ |
| A cohort of Faroese children | Serum at age 5 yr | PFHxS, PFOA, PFOS, PFNA, PFDA | Asthma or allergic diseases | Positive association between serum PFCs and increased risk of asthma or allergic diseases | Timmermann et al. [ |
| 12 healthy adult volunteers | Serum of adult | PFCs | Booster vaccination with diphtheria and tetanus | Negative association between serum PFCs and rate of increase in antibody responses | Kielsen et al. [ |
| NHANES in U.S. | Serum at age 12-19 yr | PFOS, PFOA, PFHxS | Food allergy | Positive association between serum PFCs and self-reported food allergy | Buser and Scinicariello [ |
| Adult B6C3F1 mice | Serum | PFOS | IgM production | Negative association between serum PFOS and B-cell mediated IgM production | Peden-Adams et al. [ |
| Female B6C3F1 mice | Serum | PFOS | Mortality after influenza A infection | Positive association between serum PFOS and mortality after influenza A infection | Guruge et al. [ |
PFC, perfluoroalkyl compounds; PFOS, perfluorooctane sulfonic acid; PFOA, perfluorooctanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFDA, perfluorodecanoic acid; NHANES, National Health and Nutrition Examination Survey; IgM, immunoglobulin M.